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Abstract
Strong evidence suggests that systemic inflammation and central adiposity contribute to and perpetuate met-
abolic syndrome. All of these alterations predispose individuals to type 2 diabetes mellitus (T2DM), cardio-
vascular disease, as well as Alzheimer’s disease (AD), all characterized by chronic inflammatory status. On the
other hand, extensive abnormalities in insulin and insulin-like growth factor I (IGF-I) and IGF-II signaling
mechanisms in brains with AD have been demonstrated, suggesting that AD could be a third form of diabetes.
The Src homology domain-containing inositol 5-phosphatase 2 (SHIP2) has an important role in the insulin
pathway because its over-expression causes impairment of insulin/IGF-1 signaling. Because some single-
nucleotide polymorphisms (SNP) of the gene encoding SHIP2 were significantly associated in T2DM patients
with metabolic syndrome and some related conditions, we decided to conduct a case–control study on this gene,
analyzing AD and T2DM subjects as cases and young, old, and centenarians as controls. Our results suggest a
putative correlation between the the rs144989913 SNP and aging, both successful and unsuccessful, rather than
age-related diseases. Because this SNP is an insertion/deletion of 28 bp, it might cause an alteration in SHIP2
expression. It is noteworthy that SHIP2 has been demonstrated to be a potent negative regulator of insulin
signaling and insulin sensitivity. Many studies demonstrated the association of the insulin/IGF1 pathway with
aging and longevity, so it is tempting to speculate that the found association with SHIP2 and aging might
depend on its effect on the insulin/IGF-1 pathway.
Introduction
Aging is an ineluctable process resulting from theinteraction among genetic, epigenetic, stochastic, and
lifestyle factors.1,2 However, in vivo studies in model ani-
mals demonstrate that single genetic mutations are able
to modulate life span. The insulin-like growth factor-I (IGF-I)
pathway seems to be correlated to human life span, and its
homologs are closely conserved in the main experimental
models such as yeast, nematode, and fruit fly in which mu-
tations in genes encoding proteins involved in this pathway
affect life span.3
Insulin is the most potent anabolic hormone and is essential
for appropriate tissue development, growth, and maintenance
of whole-body glucose homeostasis. Insulin resistance (IR)
reflects impairments in the insulin signaling pathway, but the
molecular mechanisms implicated are not so clear, although
the inflammatory process is involved. IR is one of the features
of metabolic syndrome, a pre-diabetic status.4,5
Interestingly, strong evidence suggests that systemic in-
flammation and central adiposity contribute to and perpet-
uate metabolic syndrome. All of these alterations predispose
individuals to type 2 diabetes mellitus (T2DM), cardiovas-
cular disease, as well as Alzheimer’s disease (AD), all
characterized by chronic inflammatory status.6–12 In 2005, a
group of American scientists hypothesized that AD could be
a third form of diabetes. They demonstrated extensive ab-
normalities in insulin and IGF-I and IGF-II signaling
mechanisms in brains with AD, showing that although each
of the corresponding growth factors is normally made in
central nervous system neurons, the expression levels are
markedly reduced in AD.13
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Today, evidence demonstrates the presence of IR in sub-
jects with neurodegeneration, such as AD or Parkinson’s
patients.14 AD, the most common form of dementia, is
characterized by accumulation of senile plaques constituted
by deposits of the abnormal amyloid protein (Ab40–42 amino
acids) and neurofibrillary tangles originating from hyper-
phosphorylation of microtubular tau protein. The amyloid
hypothesis is not unique for the pathogenesis of AD. Indeed,
different pathophysiological theories exist that focus attention
on inflammation, vascular changes, and metabolic disorders.
The most plausible hypothesis is that all of these theories are
not mutually exclusive and could be taken together. Actually,
inflammation plays a relevant role in both vascular lesions
and metabolic disorders and could be the link between AD
and T2DM.15–17 Moreover, some authors proposed the con-
cept of ‘‘metabolic cognitive syndrome’’ based on the co-
occurrence of AD and metabolic syndrome. Indeed, dementia
and metabolic syndrome present some overlaps both in pre-
disposition factors, such as diet, smoking, socio-economic
status, and lifestyle, and in altered signaling cascades, i.e.,
nutrient-sensing pathways such as the insulin pathway.18
The Src homology domain-containing inositol 5-phos-
phatase 2 (SHIP2), has an important role in the insulin
pathway. It leads to the activation of AKT, acting on gly-
cogen synthase kinase-3 (GSK3) (Fig. 1).19,20 Dysregulation
of GSK3 activity determines neuronal cell death, hyper-
phosphorylation of tau protein, and the production of amy-
loid protein with an involvement in the neuropathology
of AD.21,22 Many studies underline the role of SHIP2 as a
probable negative regulator of insulin signaling.19,23–25 A
study conducted by Kaisaki et al. in T2DM subjects dem-
onstrated a significant association between single-nucleotide
polymorphisms (SNPs) of INPPL1 (rs2276047, rs9886, and
rs144989913) and metabolic syndrome or correlated fea-
tures,26 a finding partly confirmed by another study.27
Moreover, a study conducted in non-T2DM subjects with
hypertension (one of the features of metabolic syndrome
previously associated with the SNPs), found no association,
identifying the T2DM as condition probably necessary for
the association.28
Starting from all of these studies and observations, we
decided to conduct a case–control study on this gene, ana-
lyzing AD and T2DM subjects as cases and young, old,
and centenarians as controls, with the aim to strengthen
the association between the above-mentioned age-related
diseases. In particular, we studied two polymorphisms of
INPPL1 (which encodes inositol polyphosphate-5 phos-
phatase-like 1), rs9886 and the rs144989913.
FIG. 1. Insulin-like growth factor I (IGF-1) pathway and Src homology domain-containing inositol 5-phosphatase 2
(SHIP2) action. This signaling pathway has a critical role in the determination of longevity. The bond of insulin/IGF-1 to the
specific receptor (IGF-1R/INSR) activates the phosphatidylinositol-3¢-kinase (PI3K) through the insulin-related substrate
(IRS). It leads to the activation of AKT, through phosphatidylinositol(3,4,5)-trisphosphate (PIP3), which, in turn, inhibits
Forkhead box O3A (FOXO3A). FOXO3A acts as transcription factor, activating the expression of many homeostatic genes.
In the meantime, the downstream signal activated from PIP3 leads to the activation of AKT/protein kinase B (PKB), which
phosphorylates and inactivates the glycogen synthase kinase 3 (GSK3). SHIP2 acts on the substrate lipid secondary
messenger PIP3 to produce phosphatidylinositol 3,4-diphosphate (PIP2). Thus, SHIP2 is an antagonist of PI3K that
phosphorylates PIP2 to obtain PIP3, attenuating the PI3K-mediated insulin signaling pathway.
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Material and Methods
Sample collection
Informed consent was obtained from all cases of T2DM
or guardians of AD patients and controls according to Italian
law. In all, we collected 468 whole blood samples in EDTA
Vacutainers.
Specifically, we enrolled 127 unrelated young subjects
(mean age 35) randomly selected from blood donors and
105 old people (mean age 72), as controls. They were
checked and judged to be in good health on the basis of their
clinical history and on blood tests (complete blood cell
count, erythrocyte sedimentation rate, glucose, urea nitrogen,
creatinine, electrolytes, C-reactive protein, liver function
test, iron, proteins, cholesterol, and triglycerides). Moreover,
we selected 119 subjects probably affected by AD (mean age
77) as cases. AD patients were diagnosed according to
standard clinical procedures and followed the National In-
stitute of Neurological and Communicative Disorders and
Stroke and the Alzheimer’s Disease and Related Disorders
Association (NINCDS/ADRDA) and Diagnostic and Statis-
tical Manual of Mental Disorders, Third Edition, Revised
(DSM-IIIR) criteria. Cognitive performance and alterations
were measured according to the Mini-Mental State Evalua-
tion and the Global Deterioration Scale. These cases were
defined as sporadic because their family history did not
mention any first-degree relative with dementia.29,30 A total
of 117 subjects affected by T2DM (mean age 68), diagnosed
according to joint criteria of American Diabetes Association,
the European Association for the Study of Diabetes, and the
International Diabetes Federation, were also enrolled as
cases. Moreover, we analyzed 20 DNA samples of cente-
narians belonging to our DNA bank.
Genetic analysis
Peripheral whole blood samples were collected and ge-
nomic DNA was extracted from leukocytes by a commercial
kit. We genotyped the SNP rs144989913, which is an in-
sertion/deletion (I/D) of 28 base pairs, by classic PCR and
rs9886 by amplification-refractory mutation system (ARMS
PCR). The size separation was conducted using agarose gel
electrophoresis (3%).
Statistical analysis
The data were tested by a chi-squared test for the good-
ness of fit between the observed and expected genotype
frequencies according to the Hardy–Weinberg equilibrium
(HWE). Differences in allele and genotypic frequencies of
the two SNPs among the groups were evaluated by gene
count and the chi-squared test.
Results
A total of 488 individuals have been genotyped for the
two SNPs. The frequencies of the genotypes of all SNPs
under investigation, both in cases and controls, are in HWE.
Table 1 shows the genotype and allele frequencies in all
subjects of the two SNPs of INPPL1. We did not find any
association for the rs9886 polymorphism, both for genotypic
and allelic frequencies (data not shown). The distribution of
the rs144989913 genotype between T2DM and young, old
and young, and young and centenarians is significantly
different. The frequency of the heterozygous genotype was
increased in T2DM and AD patients as well as in old and
centenarians with respect to young subjects. According to
the genotype, a significant difference in the rs144989913
allele frequencies between T2DM and young, AD and
young, old and young, and young and centenarians was
observed. There were no significant differences for genotype
and allele frequencies between T2DM and old or cente-
narians, AD and old, or centenarians and old and cente-
narians. Focusing on allelic frequencies of the D allele of
rs144989913, we highlighted, with a 3 · 2 table, a growing
significant increase ( p = 0.0016) of D with increasing age
(young = 0.39; old= 0.11; centenarians = 0.15).
Gender analysis demonstrated that the significant differ-
ence in the rs144989913 genotypic and allele frequencies
between T2DM and young, AD and young, and old and
Table 1. rs144999813 Genetic Distribution and Allele Frequency for Cases Represented by Alzheimer
Disease Subjects and Type 2 Diabetes Mellitus Subjects and Controls Represented by Young, Old,
and Centenarians Subjects and Association of the rs144999813 Between Cases and Controls
and Young and Aged People
Genotype T2DM (n = 117) (A) AD (n = 119) (B) Young (n= 127) (C) Old (n = 105) (D) Centenarian (n = 20) (E)
I/I 97 (0.83) 97 (0.81) 117 (0.92) 81 (0.77) 14 (0.70)
I/D 20 (0.17) 22 (0.19) 10 (0.08) 24 (0.13) 6 (0.30)
D/D 0 0 0 0 0
P AvsC = 0.028* BvsC = 0.013* CvsD = 0.0013* DvsE = ns*
AvsD = ns* BvsD = ns* CvsE = 0.0031*
AvsE = ns* BvsE = ns*
ALLELE
I 214 (0.91) 216 (0.91) 244 (0.96) 186 (0.88) 34 (0.85)
D 20 (0.09) 22 (0.09) 10 (0.039) 24 (0.11) 6 (0.15)
P AvsC = 0.034** BvsC = 0.017** CvsD = 0.0020** DvsE = ns**
AvsD = ns** BvsD = ns** CvsE = 0.004**
AvsE = ns** BvsE = ns**
*The significance of the different genotype distribution among groups was calculated by chi-squared test (3· 2 table).
**The significance of the different allele distribution among groups was calculated by chi-squared test (2 · 2 table).
T2DM, type 2 diabetes mellitus; AD, Alzheimer’s disease; I, insertion; D, deletion; ns, not significant.
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young are present only in males rather than in both males and
females (data not shown). Due to small number of centenar-
ians, we could not study the gender effect in this population.
Discussion
Our study concerned the association between INPPL1
SNPs and age-related diseases, aging, and longevity. The
results indicate a significant association of the rs144989913
polymorphism with both successful and unsuccessful aging.
In a previous report, rs9886 and rs144989913 were shown to
be associated, in haplotype, with rs2276047, to hypertension,
obesity, metabolic syndrome, and T2DM, but no association
with only rs2276047 was shown.26 Thus, we exclusively
analyzed the two above-mentioned SNPs but we obtained
significant results only for rs144989913.
Both genotypic and allelic frequencies of rs144989913
showed significant association of this SNP between young
and old in general, rather than between elderly and the
specific age-related diseases. The frequency of the D allele
increased from young to centenarians. Therefore, in a fur-
ther step, the life expectancy should be analyzed in aged
patients with the D allele in comparison with the I allele.
Moreover, the specific association with males in not sur-
prising because it has been claimed that males and females
follow different strategies to attain longevity, and several
case–control studies have been positive only in males.31–33
Concerning the function of SHIP2, it is noteworthy that
its acts inside the signaling cascade of insulin, hence its
alteration in terms of function and expression may cause
insulin pathway impairment. Indeed, in vivo studies, dem-
onstrated that SHIP2 is a potent negative regulator of insulin
signaling and insulin sensitivity.18,22–24 Many studies have
demonstrated the association of the insulin/IGF1 pathway
with aging and longevity. The replication of specific results
in model organisms led to conducting studies also in hu-
man.3,33 It is tempting to speculate that rs144989913 alleles
may differently influence gene expression because they
consist of a variation of 28 base pairs. They may differently
modulate the insulin pathway involved in aging and lon-
gevity, hence functional studies are mandatory to confirm
this suggestion.
In conclusion, our results are only a small contribution
to aging research, but they do represent the first study
that couples INPPL1/SHIP2 and aging. INPPL1 might be a
‘‘new’’ interesting gene in aging research, and this study
represents the first step.
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